Odds ratios for markers with readings above or below the detection limits
Marker . | Patients N = 524 . | Controls N = 628 . | Crude OR . | OR adjusted for age and smoking . | Adjusted OR* . | OR for nonsmokers only, age corrected N = 617 . | OR adjusted for traditional risk factors and for time since the event . | Adjusted OR*samples collected more than 2 years after the event N = 852 . | OR adjusted for traditional risk factors and for use of medication at time of sample collection . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Detectable versus nondetectable levels of relative mRNA | ||||||||||||||
| IL15(2) | 42 | 25 | 2.1 (1.3-3.5) | 2.2 (1.3-3.7) | 2.2 (1.3-3.7) | 2.7 (1.4-5.5) | 2.1 (1.2-3.6) | 2.4 (1.4-4.4) | 2.3 (1.2-4.1) | |||||
| MCP-2 | 31 | 23 | 1.7 (1.0-2.9) | 1.7 (1.0-3.1) | 1.8 (1.0-3.2) | 2.1 (1.0-4.5) | 2.1 (1.1-3.7) | 2.0 (1.1-3.8) | 2.0 (1.0-3.8) | |||||
| IL2 | 334 | 316 | 1.7 (1.4-2.2) | 1.7 (1.3-2.1) | 1.7 (1.3-2.2) | 2.0 (1.4-2.8) | 1.9 (1.5-2.5) | 1.2 (0.9-1.6) | 1.9 (1.5-2.6) | |||||
| IL12B | 57 | 48 | 1.5 (1.0-2.2) | 1.5 (1.0-2.4) | 1.6 (1.1-2.5) | 1.5 (0.8-2.6) | 1.7 (1.1-2.6) | 1.5 (0.9-2.5) | 1.6 (1.0-2.6) | |||||
| IL6 | 49 | 43 | 1.4 (0.9-2.1) | 1.4 (0.9-2.1) | 1.4 (0.9-2.3) | 1.4 (0.7-2.6) | 1.4 (0.9-2.2) | 1.8 (1.0-3.0) | 1.9 (1.1-3.2) | |||||
| TNF | 76 | 62 | 1.5 (1.1-2.2) | 1.5 (1.0-2.1) | 1.4 (1.0-2.1) | 1.7 (1.0-2.9) | 1.5 (1.0-2.2) | 1.6 (1.0-2.4) | 1.4 (0.9-2.1) | |||||
| IL4(2) | 266 | 248 | 1.6 (1.3-2.0) | 1.5 (1.2-1.9) | 1.4 (1.1-1.8) | 1.7 (1.2-2.4) | 1.5 (1.1-1.9) | 1.4 (1.0-1.9) | 1.4 (1.1-1.8) | |||||
| IL10 | 58 | 42 | 1.7 (1.1-2.6) | 1.5 (1.0-2.3) | 1.4 (0.9-2.1) | 2.3 (1.2-4.4) | 1.4 (0.9-2.1) | 1.3 (0.8-2.2) | 1.2 (0.7-1.9) | |||||
| IL13 | 4 | 5 | 1.0 (0.3-3.6) | 1.0 (0.2-3.9) | 1.2 (0.3-5.0) | 0.5 (0.1-4.9) | 1.2 (0.3-5.0) | 0.4 (0.0-4.0) | 2.1 (0.4-10.1) | |||||
| TF | 8 | 7 | 1.4 (0.5-3.8) | 1.2 (0.4-3.4) | 1.2 (0.4-3.7) | 0.4 (0.0-3.7) | 1.2 (0.4-3.6) | 1.1 (0.3-3.8) | 1.3 (0.4-4.4) | |||||
| MCP-1 | 120 | 128 | 1.2 (0.9-1.5) | 1.1 (0.8-1.4) | 1.2 (0.9-1.6) | 1.0 (0.6-1.5) | 1.1 (0.8-1.5) | 1.3 (0.9-1.9) | 1.2 (0.8-1.6) | |||||
| NFKB2 | 152 | 152 | 1.3 (1.0-1.7) | 1.2 (0.9-1.6) | 1.2 (0.9-1.6) | 1.4 (0.9-2.0) | 1.2 (0.9-1.6) | 1.4 (1.0-1.9) | 1.3 (0.9-1.8) | |||||
| IL4(1) | 110 | 138 | 1.0 (0.7-1.3) | 0.9 (0.7-1.2) | 0.9 (0.7-1.2) | 0.9 (0.6-1.4) | 1.0 (0.7-1.3) | 0.8 (0.6-1.2) | 0.9 (0.6-1.2) | |||||
| IL1A | 189 | 291 | 0.7 (0.5-0.8) | 0.6 (0.5-0.8) | 0.6 (0.5-0.8) | 0.5 (0.4-0.7) | 0.7 (0.5-0.9) | 0.5 (0.4-0.7) | 0.6 (0.4-0.8) | |||||
| Marker with levels above the upper detection limit versus levels within the detection limits | ||||||||||||||
| PTP4A2† | 428† | 437† | 1.8 (1.3-2.3) | 1.7 (1.2-2.2) | 1.7 (1.2-2.3) | 1.8 (1.2-2.7)‡ | 1.8 (1.3-2.5) | 2.1 (1.4-3.1)# | 1.9 (1.4-2.6) | |||||
Marker . | Patients N = 524 . | Controls N = 628 . | Crude OR . | OR adjusted for age and smoking . | Adjusted OR* . | OR for nonsmokers only, age corrected N = 617 . | OR adjusted for traditional risk factors and for time since the event . | Adjusted OR*samples collected more than 2 years after the event N = 852 . | OR adjusted for traditional risk factors and for use of medication at time of sample collection . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Detectable versus nondetectable levels of relative mRNA | ||||||||||||||
| IL15(2) | 42 | 25 | 2.1 (1.3-3.5) | 2.2 (1.3-3.7) | 2.2 (1.3-3.7) | 2.7 (1.4-5.5) | 2.1 (1.2-3.6) | 2.4 (1.4-4.4) | 2.3 (1.2-4.1) | |||||
| MCP-2 | 31 | 23 | 1.7 (1.0-2.9) | 1.7 (1.0-3.1) | 1.8 (1.0-3.2) | 2.1 (1.0-4.5) | 2.1 (1.1-3.7) | 2.0 (1.1-3.8) | 2.0 (1.0-3.8) | |||||
| IL2 | 334 | 316 | 1.7 (1.4-2.2) | 1.7 (1.3-2.1) | 1.7 (1.3-2.2) | 2.0 (1.4-2.8) | 1.9 (1.5-2.5) | 1.2 (0.9-1.6) | 1.9 (1.5-2.6) | |||||
| IL12B | 57 | 48 | 1.5 (1.0-2.2) | 1.5 (1.0-2.4) | 1.6 (1.1-2.5) | 1.5 (0.8-2.6) | 1.7 (1.1-2.6) | 1.5 (0.9-2.5) | 1.6 (1.0-2.6) | |||||
| IL6 | 49 | 43 | 1.4 (0.9-2.1) | 1.4 (0.9-2.1) | 1.4 (0.9-2.3) | 1.4 (0.7-2.6) | 1.4 (0.9-2.2) | 1.8 (1.0-3.0) | 1.9 (1.1-3.2) | |||||
| TNF | 76 | 62 | 1.5 (1.1-2.2) | 1.5 (1.0-2.1) | 1.4 (1.0-2.1) | 1.7 (1.0-2.9) | 1.5 (1.0-2.2) | 1.6 (1.0-2.4) | 1.4 (0.9-2.1) | |||||
| IL4(2) | 266 | 248 | 1.6 (1.3-2.0) | 1.5 (1.2-1.9) | 1.4 (1.1-1.8) | 1.7 (1.2-2.4) | 1.5 (1.1-1.9) | 1.4 (1.0-1.9) | 1.4 (1.1-1.8) | |||||
| IL10 | 58 | 42 | 1.7 (1.1-2.6) | 1.5 (1.0-2.3) | 1.4 (0.9-2.1) | 2.3 (1.2-4.4) | 1.4 (0.9-2.1) | 1.3 (0.8-2.2) | 1.2 (0.7-1.9) | |||||
| IL13 | 4 | 5 | 1.0 (0.3-3.6) | 1.0 (0.2-3.9) | 1.2 (0.3-5.0) | 0.5 (0.1-4.9) | 1.2 (0.3-5.0) | 0.4 (0.0-4.0) | 2.1 (0.4-10.1) | |||||
| TF | 8 | 7 | 1.4 (0.5-3.8) | 1.2 (0.4-3.4) | 1.2 (0.4-3.7) | 0.4 (0.0-3.7) | 1.2 (0.4-3.6) | 1.1 (0.3-3.8) | 1.3 (0.4-4.4) | |||||
| MCP-1 | 120 | 128 | 1.2 (0.9-1.5) | 1.1 (0.8-1.4) | 1.2 (0.9-1.6) | 1.0 (0.6-1.5) | 1.1 (0.8-1.5) | 1.3 (0.9-1.9) | 1.2 (0.8-1.6) | |||||
| NFKB2 | 152 | 152 | 1.3 (1.0-1.7) | 1.2 (0.9-1.6) | 1.2 (0.9-1.6) | 1.4 (0.9-2.0) | 1.2 (0.9-1.6) | 1.4 (1.0-1.9) | 1.3 (0.9-1.8) | |||||
| IL4(1) | 110 | 138 | 1.0 (0.7-1.3) | 0.9 (0.7-1.2) | 0.9 (0.7-1.2) | 0.9 (0.6-1.4) | 1.0 (0.7-1.3) | 0.8 (0.6-1.2) | 0.9 (0.6-1.2) | |||||
| IL1A | 189 | 291 | 0.7 (0.5-0.8) | 0.6 (0.5-0.8) | 0.6 (0.5-0.8) | 0.5 (0.4-0.7) | 0.7 (0.5-0.9) | 0.5 (0.4-0.7) | 0.6 (0.4-0.8) | |||||
| Marker with levels above the upper detection limit versus levels within the detection limits | ||||||||||||||
| PTP4A2† | 428† | 437† | 1.8 (1.3-2.3) | 1.7 (1.2-2.2) | 1.7 (1.2-2.3) | 1.8 (1.2-2.7)‡ | 1.8 (1.3-2.5) | 2.1 (1.4-3.1)# | 1.9 (1.4-2.6) | |||||
Results of a stratified analysis on men who were nonsmokers at the index date and sampling date are shown in column 7. Subsequent columns show odds ratios adjusted for traditional risk factors and for time since the event (column 8), adjusted odds ratios using only samples collected more than 2 years after the event (column 9), and adjustment for use of medication at time of sample collection (last column). 95% confidence intervals are shown in parentheses.
Adjusted for age, smoking, use of medication for hypertension or hypercholesterolemia, diabetes, BMI, alcohol habit, and quartile of CRP.
Out of 518 cases and 599 controls.
Out of 592 samples.
Out of 841 samples.